Interest of a Targeted Therapy for the Treatment of a Severe Form of Hypersensitivity to Drug (DRESS Syndrome) (BENRADRESS)

University Hospital, Lille

Status and phase: Not yet enrolling; Phase 2

Conditions: DRESS Syndrome

Treatments: Drug: Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride; Drug: Benralizumab 30 MG/ML [Fasenra]

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT06734884

2022-502750-14-00 (EU Trial (CTIS) Number)

2020_57

Details and patient eligibility

About

Drug Reaction with eosinophilia and Systemic Symptoms (DRESS) is a rare and severe multiorgan drug reaction whose pathophysiological mechanisms underlying remain unclear, but may involve the role of several immune cells like eosinophils. iIndeed,the number of eosinophils is increased in blood and/or in organs tiisues in at least 50% of patients with DRESS. There is no specific treatment available. The standard of care is corticosteroids, but they may be inefficient or poorly tolerated. The aim of this research is to find out whether a specific treatment of the immunological response in DRESS syndrome would be useful in combination with corticosteroids to speed up the recovery from DRESS syndrome and therefore reduce the total length of your hospital stay when your illness is being managed. This a multicenter, international, prospective, interventional study, double-blinded, placebo-controlled, randomized, in two balanced parallel groups, one receiving the standard of care (topical or systemic corticosteroids, according to the severity of DRESS syndrome) and the other one corticsoteroids and a targeted therapy against eosinophils (benralizumab, already available in other eosinophilic diseases like asthma).

Enrollment: 96 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Adult patients (minimum 18year-old)

2. diagnosed at D0 (= baseline and inclusion) with DRESS defined by:

   1. with a REGIScar score at D0 calculated at at least 4 (4 or 5: probable DRESS; >5: definite case of DRESS), see Annex: REGIScar criteria

   2. Skin eruption with an onset considered as compatible with a DRESS syndrome according to the investigator's opinion after the uptake of one or several drug(s)

   3. AND Fever ≥ 38°C at the time of the examination or notion of a thermal peak ≥ 38°C in the preceding 72 hours.

   4. At least 1 organ disorder compatible with the diagnosis of DRESS syndrome among the following disorders:

      • Adenopathies present in at least 2 different sites and ≥ 1 cm in size

      • Acute hepatitis defined by :

        • Elevation of liver enzymes in serum: ALAT (Alanine Aminotransferase) and/or ASAT (Aspartate Aminotransferase)
        • AND/OR an increase in serum total bilirubin, according to the standards of the local analysis laboratory (in the absence of a history of liver disease: ASAT and/or ALAT ≥ 3N (=3 times normal)
        • AND/OR total bilirubin ≥ 2N

      • Acute renal failure defined by :

        • An increase in creatinine according to local laboratory standards
        • AND a sterile cytobacteriological examination (in the absence of a history of renal disease: creatininaemia ≥ 1.5N
        • AND/OR increase in creatinine ≥ 0.3 mg/dl (or ≥ 26.5 mol/L)
        • AND/OR urine output < 0.3 ml/kg/h (over ≥ 24h).

      • Pulmonary impairment defined by:

        • Oxygen saturation (SpO2) measured by pulse oximetry ≤ 95% in room air
        • And/or the presence of an interstitial syndrome on a standard chest X-ray or a CT scan of the chest (in the absence of any other cause of lung damage).

3. With eosinophilia (blood eosinophil count ≥ 500/mm3 or ≥0.5 G/L).

4. Patient having given written informed consent

5. patient with social insurance

Exclusion criteria

1. Patients <18 year-old
2. Patients with DRESS with REGIScar score <4
3. Patients without skin eruption at baseline
4. Eosinophils blood count <500/mm3 or < 0.5 G/L at baseline
5. Patients with contra-indication to blood samples dedicated to the biocollection, according to the investigator's opinion
6. Patients with contra-indication to stop the culprit drug(s) involved in DRESS
7. Past history of hypersensitivity to biological drugs
8. Patients who received a previous anti-IL5 or anti-IL5 receptor therapy within 5 half lives (= 4 months) before inclusion
9. Patients with a contra-indication of topical corticosteroids (mainly a past history of contact eczema with clobetasol propionate)
10. Pregnancy and lactation

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

96 participants in 2 patient groups, including a placebo group

Benralizumab

Experimental group

Treatment:

Drug: Benralizumab 30 MG/ML [Fasenra]

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride